NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity.
Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. This approach could be particularly valuable for Ebola, a severe and often fatal disease for which treatment options are limited.
The potential of an oral treatment for Ebola is significant, as current therapies often require intravenous administration, which can be challenging in outbreak settings. If successful, NV-387 Oral Gummies could offer a more accessible option for patients in remote areas. The company’s focus on broad-spectrum antivirals also positions it to address other viral threats. According to the company’s website, www.nanoviricides.com, NanoViricides is developing drugs against a range of viruses including RSV, COVID, Influenza, and MPOX/Smallpox.
Investors can find the latest news and updates relating to NNVC in the company’s newsroom at https://nnw.fm/NNVC. For a full view of the press release, visit https://nnw.fm/9fDB5.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. The platform also offers corporate communications solutions tailored to clients’ needs.
NanoViricides’ progress in the Ebola trial represents a critical step in the development of a novel antiviral therapy. While the path to regulatory approval is lengthy and uncertain, the company’s efforts could contribute to global health security by providing new tools to combat viral outbreaks. The results of the Phase IIA trial will determine whether NV-387 advances to the next stage of clinical testing. For full terms of use and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.
